HIV patients can now get monthly, FDA-approved injections, replacing multiple daily treatments

Print Friendly, PDF & Email

The Food and Drug Administration on [January 21] approved a combination of two monthly shots for treatment of H.I.V. in patients in stable condition. The treatment is called Cabenuva.

One of the two shots also has been shown to be as effective at preventing H.I.V. infection as a pill taken daily, a treatment strategy called pre-exposure prophylaxis, or PrEP. But the approval on [January 21] covers only Cabenuva’s use as a treatment.

Many people struggle to take the pills they need every day, for a variety of reasons. The consequences for people with H.I.V. can be significant, because missed pills give the virus opportunities to become resistant to the medications.

And then there is the stigma of daily pill use, which is both societal and psychological, said Dr. Tom Giordano, chief of infectious diseases at Baylor College of Medicine in Houston, who was not involved in the trials.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

Nine in 10 people in a trial of Cabenuva said they preferred the monthly injections to taking a pill every day. “You get your shot and forget about it till the next month,” Dr. Giordano said. “That’s great, and will help people who don’t want the reminder of stigma or taking pills every day.”

Read the original post

Related article:  Why are Alzheimer’s and dementia rates falling in Europe and the U.S.?
Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

The U.S. averaged fewer than 40,000 new cases per day over the past week. That’s a 21% improvement over the ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists